Compare SR & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SR | ICUI |
|---|---|---|
| Founded | 1857 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 3.2B |
| IPO Year | N/A | 1992 |
| Metric | SR | ICUI |
|---|---|---|
| Price | $88.27 | $147.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $85.91 | ★ $183.60 |
| AVG Volume (30 Days) | ★ 454.1K | 317.4K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ 4.30 | N/A |
| EPS | ★ 4.37 | N/A |
| Revenue | ★ $2,476,400,000.00 | $2,320,363,000.00 |
| Revenue This Year | $13.31 | N/A |
| Revenue Next Year | $3.24 | N/A |
| P/E Ratio | $20.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $64.44 | $107.00 |
| 52 Week High | $91.11 | $175.51 |
| Indicator | SR | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 56.58 | 67.36 |
| Support Level | $84.78 | $131.99 |
| Resistance Level | $87.12 | $153.63 |
| Average True Range (ATR) | 1.93 | 5.38 |
| MACD | -0.20 | 1.22 |
| Stochastic Oscillator | 54.84 | 74.31 |
Spire Inc. is the holding company for Spire Missouri, Spire Alabama, other gas utilities, and gas-related businesses, focused on growing organically, investing in infrastructure, and advancing through innovation. Its three segments are Gas Utility, Gas Marketing, and Midstream. The Gas Utility segment is the core business and includes Spire Missouri, Spire Alabama, and Spire EnergySouth. The Gas Marketing segment includes Spire Marketing, which provides non-regulated natural gas services across the U.S. The Midstream segment includes Spire Storage, Spire STL Pipeline, and Spire MoGas Pipeline. The majority of revenue comes from Gas Utility.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.